TECENTRIQ
1200mgTECENTRIQ1200mg
TECENTRIQ (atezolizumab) 1200mg is a PD-L1 checkpoint inhibitor immunotherapy for lung cancer, bladder cancer, triple-negative breast cancer, and hepatocellular carcinoma.
Key Benefits
- PD-L1 targeted immunotherapy
- Multiple cancer type approvals
- Flexible dosing schedules (2, 3, or 4 weeks)
- Combination options with chemotherapy and AVASTIN
- Authentic Roche product with documentation
- Cold chain shipping worldwide
Contact Us for Pricing
Get competitive wholesale pricing for TECENTRIQ 1200mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How TECENTRIQ Works
TECENTRIQ works by targeting PD-L1 (Programmed Death-Ligand 1), a protein expressed on tumor cells and tumor-infiltrating immune cells:
1. **PD-L1 Binding:** TECENTRIQ binds to PD-L1, preventing it from interacting with both PD-1 and B7.1 (CD80) receptors on T-cells.
2. **Dual Receptor Blockade:** By blocking PD-L1 binding to both PD-1 and B7.1, TECENTRIQ may provide more complete inhibition of the checkpoint pathway compared to PD-1 inhibitors alone.
3. **T-Cell Activation:** With the PD-L1/PD-1 "brake" released, T-cells can effectively recognize and attack cancer cells.
4. **Preserved Immune Tolerance:** TECENTRIQ's mechanism may preserve the PD-L2/PD-1 interaction, which could be important for maintaining immune tolerance and reducing certain side effects.
About TECENTRIQ 1200mg
TECENTRIQ (atezolizumab) 1200mg/20mL by Roche is a cutting-edge PD-L1 blocking antibody that represents the latest advancement in cancer immunotherapy. Unlike PD-1 inhibitors, TECENTRIQ directly targets PD-L1 on tumor cells and tumor-infiltrating immune cells, providing a complementary approach to checkpoint inhibition. TECENTRIQ is FDA-approved for non-small cell lung cancer (both non-squamous and squamous), extensive-stage small cell lung cancer, urothelial carcinoma, triple-negative breast cancer (PD-L1 positive), hepatocellular carcinoma, and melanoma. It can be used as monotherapy or in combination with other agents including chemotherapy and AVASTIN. As a licensed pharmaceutical supplier in Turkey, we provide authentic Roche TECENTRIQ with complete documentation, proper cold chain handling, and competitive wholesale pricing for healthcare providers worldwide. Contact us via WhatsApp for availability and pricing information.
Common Uses
- Non-small cell lung cancer (NSCLC)
- Extensive-stage small cell lung cancer
- Urothelial carcinoma
- Triple-negative breast cancer (PD-L1+)
- Hepatocellular carcinoma
- Melanoma
Dosage Information
TECENTRIQ dosing is weight-independent (flat dosing):
Standard Dosing:
Combination Regimens (examples):
Administration:
Continue until disease progression or unacceptable toxicity.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store TECENTRIQ vials in the original carton at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake. Protect from light.
Diluted Solution:
TECENTRIQ vials are single-dose. Discard any unused portion.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About TECENTRIQ
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
